1. BioMarin will host a Q1 2025 financial results call on May 1. 2. CEO Alexander Hardy will discuss company updates during this conference. 3. The call will be accessible through the BioMarin investor website. 4. BioMarin focuses on genetic therapies, improving patient outcomes significantly.
The upcoming call may provide insights, but no immediate catalysts are indicated.
Investors seek guidance from earnings calls; results can influence stock sentiment.
Results and updates from the call will have an immediate but limited market impact.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update.
U.S. / Canada Dial-in Number: 888-596-4144
International Dial-in Number: 646-968-2525
Conference Call ID: 4327591
U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 4327591
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.
BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com.
Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
Media
Marni Kottle
BioMarin Pharmaceutical Inc.
(650) 374-2803
SOURCE BioMarin Pharmaceutical Inc.